Duke Health is leading its first clinical trial under a large federal initiative to develop a new-generation flu vaccine.
The phase 1 clinical trial, which launched last month, is testing the safety of a vaccine candidate devised under the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. CIVICs is a multi-million-dollar investment by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to develop a modern vaccine that provides longer and broader protection against both seasonal and pandemic influenza viruses.
Read the full article here.